Related Experiment Video
Updated: Aug 20, 2026
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
Simvastatin induces death of multiple myeloma cell lines
Naomi Gronich1, Liat Drucker, Hava Shapiro
1Department of Medicine, Laboratories, Sapir Medical Center, Meir Hospital, Kfar-Saba, Israel.
Background:
Accumulating reports indicate that statins widely prescribed for hypercholesteromia have antineoplastic activity. We hypothesized that because statins inhibit farnesylation of Ras that is often mutated in multiple myeloma (MM), as well as the production of interleukin (IL)-6, a key cytokine in MM, they may have antiproliferative and/or proapoptotic effects in this malignancy.
Methods:
U266, RPMI 8226, and ARH77 were treated with simvastatin (0-30 microM) for 5 days. The following aspects were evaluated: viability (IC50), cell cycle, cell death, cytoplasmic calcium ion levels, supernatant IL-6 levels, and tyrosine kinase activity.
Results:
Exposure of all cell lines to simvastatin resulted in reduced viability with IC50s of 4.5 microM for ARH77, 8 microM for RPMI 8226, and 13 microM for U266. The decreased viability is attributed to cell-cycle arrest (U266, G1; RPMI 8226, G2M) and cell death. ARH77 underwent apoptosis, whereas U266 and RPMI 8226 displayed a more necrotic form of death. Cytoplasmic calcium levels decreased significantly in all treated cell lines. IL-6 secretion from U266 cells was abrogated on treatment with simvastatin, whereas total tyrosine phosphorylation was unaffected.
Conclusions:
Simvastatin displays significant antimyeloma activity in vitro. Further research is warranted for elucidation of the modulated molecular pathways and clinical relevance.
Insights
Simvastatin, a cholesterol-lowering drug, shows significant antimyeloma activity by reducing cancer cell viability and inducing cell death in multiple myeloma models. Further research is needed to explore its clinical relevance.
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Background:
- Statins, commonly prescribed for hypercholesterolemia, exhibit potential antineoplastic effects.
- Statins inhibit Ras farnesylation and reduce interleukin-6 (IL-6) production, key factors in multiple myeloma (MM).
Purpose of the Study:
- To investigate the antiproliferative and proapoptotic effects of simvastatin in multiple myeloma cell lines.
- To evaluate simvastatin's impact on MM cell viability, cell cycle, cell death, and IL-6 secretion.
Main Methods:
- Multiple myeloma cell lines (U266, RPMI 8226, ARH77) were treated with varying concentrations of simvastatin.
- Assays included viability (IC50), cell cycle analysis, apoptosis/necrosis detection, cytoplasmic calcium levels, and IL-6 secretion measurement.
Main Results:
- Simvastatin significantly reduced viability across all tested cell lines, with IC50 values ranging from 4.5 to 13 microM.
- Decreased viability was linked to cell-cycle arrest and induction of cell death (apoptosis or necrosis).
- Simvastatin abrogated IL-6 secretion in U266 cells and decreased cytoplasmic calcium levels.
Conclusions:
- Simvastatin demonstrates potent in vitro antimyeloma activity.
- The findings support further investigation into simvastatin's molecular pathways and clinical applicability for multiple myeloma treatment.
Related Concept Videos
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
01:10Drugs that Destabilize Microtubules